222 BERKELEY STREET, BOSTON, MA
Announces Changes to Board of Directors
Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Investor Presentation
Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Director Resignation - Camille L. Bedrosian Steps Down from Board
FY 2025
Q3
Q2
Q1
FY 2023
Q2 amended
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report